16.5 1 (6.45%) | 02-11 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 23.1 | 1-year : | 26.98 |
Resists | First : | 19.78 | Second : | 23.1 |
Pivot price | 15.66 ![]() |
|||
Supports | First : | 13.86 | Second : | 10.19 |
MAs | MA(5) : | 16.69 ![]() |
MA(20) : | 14.44 ![]() |
MA(100) : | 0 | MA(250) : | 0 | |
MACD | MACD : | 0.8 ![]() |
Signal : | 0.6 ![]() |
%K %D | K(14,3) : | 58.3 ![]() |
D(3) : | 64.4 ![]() |
RSI | RSI(14): 55.8 ![]() |
|||
52-week | High : | 23 | Low : | 8.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IZTC ] has closed below upper band by 40.3%. Bollinger Bands are 0% narrower than normal.
If tomorrow: | Open lower | Open higher |
High: | 17.01 - 17.11 | 17.11 - 17.21 |
Low: | 14.95 - 15.06 | 15.06 - 15.17 |
Close: | 16.32 - 16.49 | 16.49 - 16.66 |
Invizyne Technologies, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
Wed, 12 Feb 2025
Rebranding Invizyne to eXoZymes Signifies a Sustainable - GlobeNewswire
Wed, 12 Feb 2025
From Lab to Factory: AI-Engineered 'Exozymes' Promise Weeks-Fast Chemical Production Revolution - StockTitan
Tue, 11 Feb 2025
Invizyne Technologies, Inc. will Change its Ticker to EXOZ from IZTC -February 12, 2025 at 12:00 am EST - Marketscreener.com
Mon, 10 Feb 2025
Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - The Manila Times
Mon, 10 Feb 2025
Major Biotech Rebrand: Invizyne Becomes eXoZymes - Strategic Move in Enzyme Manufacturing Space - StockTitan
Thu, 14 Nov 2024
Invizyne Technologies Completes $15M IPO, Makes NASDAQ Debut Under IZTC - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 10 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 76.3 (%) |
Shares Short | 10 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.68e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 704 % |
Return on Assets (ttm) | 833.6 % |
Return on Equity (ttm) | -88.3 % |
Qtrly Rev. Growth | -700 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -0.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0 |
Dividend | 0 |
Forward Dividend | 23200 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |